BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 10800057)

  • 21. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders.
    Hassan M; Fasth A; Gerritsen B; Haraldsson A; Syrůcková Z; van den Berg H; Sandström M; Karlsson M; Kumlien S; Vossen J
    Bone Marrow Transplant; 1996 Nov; 18(5):843-50. PubMed ID: 8932835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data.
    Carreras E; Cahn JY; Puozzo C; Kröger N; Sanz G; Buzyn A; Bacigalupo A; Vernant JP
    Anticancer Res; 2010 Jul; 30(7):2977-84. PubMed ID: 20683042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics.
    Brice K; Valerie B; Claire G; Valerie M; Yves B; Gilles A; Nathalie B
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):135-43. PubMed ID: 17952879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of busulfan area under the curve with veno-occlusive disease following BMT.
    Dix SP; Wingard JR; Mullins RE; Jerkunica I; Davidson TG; Gilmore CE; York RC; Lin LS; Devine SM; Geller RB; Heffner LT; Hillyer CD; Holland HK; Winton EF; Saral R
    Bone Marrow Transplant; 1996 Feb; 17(2):225-30. PubMed ID: 8640171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring.
    Mamlouk K; Saracino G; Berryman RB; Fay JW; Pineiro LA; Vance EA; White M; Sandler I; Agura ED
    Bone Marrow Transplant; 2005 Apr; 35(8):747-54. PubMed ID: 15750611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Busulphan given as four single daily doses of 150 mg/m2 is safe and effective in children of all ages.
    Shaw PJ; Nath C; Berry A; Earl JW
    Bone Marrow Transplant; 2004 Aug; 34(3):197-205. PubMed ID: 15195074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pulmonary complications of bone marrow transplantation: a comparison of total body irradiation and cyclophosphamide to busulfan and cyclophosphamide.
    Hartsell WF; Czyzewski EA; Ghalie R; Kaizer H
    Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):69-73. PubMed ID: 7536723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone marrow transplantation in thalassemia major patients using "short" anti-thymocyte globulin therapy in Shiraz, Southern Iran.
    Zakerinia M; Khojasteh HN; Ramzi M; Haghshenas M
    Transplant Proc; 2005 Dec; 37(10):4477-81. PubMed ID: 16387149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation.
    Crilley P; Topolsky D; Styler MJ; Bernstein E; Resnick K; Mullaney R; Bulova S; Brodsky I; Marks DI
    Bone Marrow Transplant; 1995 Mar; 15(3):361-5. PubMed ID: 7599559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone marrow transplantation from matched related donors for patients with Fanconi anemia using low-dose busulfan and cyclophosphamide as conditioning.
    Torjemane L; Ladeb S; Ben Othman T; Abdelkefi A; Lakhal A; Ben Abdeladhim A
    Pediatr Blood Cancer; 2006 Apr; 46(4):496-500. PubMed ID: 16333862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Total body irradiation in bone marrow transplantation: fractionated vs single dose. Acute toxicity and preliminary results.
    Valls A; Grañena A; Carreras E; Ferrer E; Algara M
    Bull Cancer; 1989; 76(8):797-804. PubMed ID: 2695178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
    Jerjis S; Roovers E; Muus P; Schaap N; de Witte T
    Bone Marrow Transplant; 1998 Jul; 22(1):13-9. PubMed ID: 9678790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
    Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
    Bleyzac N; Souillet G; Magron P; Janoly A; Martin P; Bertrand Y; Galambrun C; Dai Q; Maire P; Jelliffe RW; Aulagner G
    Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safe administration of oral BU twice daily during conditioning for stem cell transplantation in a paediatric population: a comparative study between the standard 4-dose and a 2-dose regimen.
    Mellgren K; Nilsson C; Fasth A; Abrahamsson J; Winiarski J; Ringdén O; Hassan M
    Bone Marrow Transplant; 2008 Apr; 41(7):621-5. PubMed ID: 18084338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia conditioned with busulfan, cyclophosphamide and melphalan.
    Carpenter PA; Marshall GM; Giri N; Vowels MR; Russell SJ
    Bone Marrow Transplant; 1996 Sep; 18(3):489-94. PubMed ID: 8879607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New preparative regimens with diaziquone or cytarabine in combination with busulfan and cyclophosphamide.
    Devine SM; Geller RB; Holland HK; Wingard JR; Saral R
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):56-63; quiz 64. PubMed ID: 8342077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis.
    Hartman AR; Williams SF; Dillon JJ
    Bone Marrow Transplant; 1998 Sep; 22(5):439-43. PubMed ID: 9733266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relapse after allogeneic bone marrow transplantation for refractory anemia is increased by shielding lungs and liver during total body irradiation.
    Anderson JE; Appelbaum FR; Schoch G; Barnett T; Chauncey TR; Flowers ME; Storb R
    Biol Blood Marrow Transplant; 2001; 7(3):163-70. PubMed ID: 11302550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of thiotepa in allogeneic bone marrow transplantation for genetic diseases.
    Rosales F; Peylan-Ramu N; Cividalli G; Varadi G; Or R; Naparstek E; Slavin S; Nagler A
    Bone Marrow Transplant; 1999 May; 23(9):861-5. PubMed ID: 10338039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.